NO995231L - Terapeutisk behandling av hudlidelser - Google Patents

Terapeutisk behandling av hudlidelser

Info

Publication number
NO995231L
NO995231L NO995231A NO995231A NO995231L NO 995231 L NO995231 L NO 995231L NO 995231 A NO995231 A NO 995231A NO 995231 A NO995231 A NO 995231A NO 995231 L NO995231 L NO 995231L
Authority
NO
Norway
Prior art keywords
therapeutic treatment
skin disorders
vascular permeability
dermatitis
phemigoid
Prior art date
Application number
NO995231A
Other languages
English (en)
Other versions
NO995231D0 (no
Inventor
Michael R Jirousek
Lawrence E Stramm
Louis Vignati
Douglas K Ways
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO995231D0 publication Critical patent/NO995231D0/no
Publication of NO995231L publication Critical patent/NO995231L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

En metode til å redusere eller inhibere vaskulær permeabilitet, spesielt den økte vaskulære permeabili-teten assosiert med VPF/VEGF, og hudødem som vises ved blæreformet phemigoid, multiformet erytem, herpeslignende dermatitt, kontaktdermatitt/forsinket hypersensitivitet blir lagt frem, spesielt ved å bruke den P-isoenzymselektive PKC-inhibitoren, (S)-3,4-[N,N'-1,1 '-((2 "-etoksy)-3''' (0)-4"' -(N,N-dimety lamino)-butan)-bis-(3,3'-indolyl)]-l(H)-pyrrol-2,5-dion og dens farmasøytiske akseptable salter.
NO995231A 1997-04-30 1999-10-26 Terapeutisk behandling av hudlidelser NO995231L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4443197P 1997-04-30 1997-04-30
PCT/US1998/007808 WO1998048795A1 (en) 1997-04-30 1998-04-21 Therapeutic treatment for skin disorders

Publications (2)

Publication Number Publication Date
NO995231D0 NO995231D0 (no) 1999-10-26
NO995231L true NO995231L (no) 1999-12-27

Family

ID=21932346

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995231A NO995231L (no) 1997-04-30 1999-10-26 Terapeutisk behandling av hudlidelser

Country Status (16)

Country Link
US (1) US6093740A (no)
EP (1) EP0903145A3 (no)
JP (1) JP2002501501A (no)
KR (1) KR20010020381A (no)
CN (1) CN1259866A (no)
AU (1) AU7131898A (no)
BR (1) BR9809343A (no)
CA (1) CA2289257A1 (no)
EA (1) EA199900987A1 (no)
HU (1) HUP0002836A2 (no)
ID (1) ID23528A (no)
IL (1) IL132520A0 (no)
NO (1) NO995231L (no)
PL (1) PL336760A1 (no)
TR (1) TR199902682T2 (no)
WO (1) WO1998048795A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4731016B2 (ja) * 1998-12-22 2011-07-20 ジェネンテック， インコーポレイテッド 血管内皮細胞増殖因子アンタゴニストとその用途
AU781444B2 (en) * 1999-12-22 2005-05-26 Scripps Research Institute, The Angiogenesis and vascular permeability modulators and inhibitors
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US20070032479A1 (en) * 2003-12-03 2007-02-08 Leventer Steven M Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines
DE102004019413A1 (de) * 2004-04-19 2005-11-24 Phenos Gmbh Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
ES2396440T3 (es) * 2006-01-18 2013-02-21 The General Hospital Corporation Métodos de aumentar la función linfática
US7455447B2 (en) * 2006-05-19 2008-11-25 Mediatek Inc. Method and apparatus for a portable device
CN101380317B (zh) * 2007-09-07 2010-12-08 英属开曼群岛商安盛开发药物股份有限公司 减缓搔痒症的药学组合物
MX349146B (es) * 2011-06-13 2017-07-14 Univ Illinois Composiciones de peptidos y metodos para tratar lesion pulmonar, asma, anafilaxis, angioedema, sindromes de permeabilidad vascular sistemica, y congestion nasal.
WO2018118874A1 (en) * 2016-12-19 2018-06-28 Chromaderm, Inc. Methods of treating hyperpigmentation disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
UA44690C2 (uk) * 1993-12-07 2002-03-15 Елі Ліллі Енд Компані Макроциклічна сполука іміду біс-індол-малеїнової кислоти, спосіб її одержання та фармацевтична композиція, макроциклічні сполуки іміду біс-індол-малеїнової кислоти та біс-індол-малеїнового ангідриду, спосіб одержання (варіанти)
IL111851A (en) * 1993-12-07 1998-09-24 Lilly Co Eli Improved synthesis of bisindolylsimilides and process for its preparation
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
BR9611724A (pt) * 1995-11-20 1999-06-01 Lilly Co Eli Inibidor de quinase c de proteína
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
PL329851A1 (en) * 1996-05-01 1999-04-12 Lilly Co Eli Treatment of diseases associated with vegf

Also Published As

Publication number Publication date
BR9809343A (pt) 2000-07-04
EA199900987A1 (ru) 2000-08-28
EP0903145A3 (en) 2001-02-07
JP2002501501A (ja) 2002-01-15
HUP0002836A2 (hu) 2001-02-28
IL132520A0 (en) 2001-03-19
CA2289257A1 (en) 1998-11-05
AU7131898A (en) 1998-11-24
US6093740A (en) 2000-07-25
ID23528A (id) 2000-04-27
WO1998048795A1 (en) 1998-11-05
PL336760A1 (en) 2000-07-17
TR199902682T2 (xx) 2000-05-22
CN1259866A (zh) 2000-07-12
NO995231D0 (no) 1999-10-26
KR20010020381A (ko) 2001-03-15
EP0903145A2 (en) 1999-03-24

Similar Documents

Publication Publication Date Title
NO995231L (no) Terapeutisk behandling av hudlidelser
HK1083203A1 (en) The use of intratumorally administered lactoferrin in the treatment of malignant neoplasms
AU6825300A (en) Compounds
WO2006060507A3 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
CA2253613A1 (en) Therapeutic treatment for vegf related occular diseases
DE60215951D1 (de) Piperidinderivate als antibakterielle mittel
NO985066L (no) Terapeutisk behandling for VEGF-relaterte sykdommer
NO954878L (no) Pyrrolderivater
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
EP1631297A4 (en) TREATMENT OF IMMUNOSTIC DISEASES WITH ACTIVE VITAMIN D COMPOUNDS ALONE OR IN COMBINATION WITH OTHER THERAPEUTICS
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
AU3476397A (en) Therapeutic treatment for cardiovascular diseases
CA2441461A1 (en) Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia
WO2001074365A3 (en) An efficacious dosage regimen of galantamine that reduces side effects
TR200102512T2 (tr) Tüm ruhsal bozukluklar, adaptasyon bozuklukları ve çeşitli kaygı-depresyon bozukluklarının tedavisinde ya da önlenmesinde yararlı tıbbi ürünlerin hazırlanması için saredutan ve onun farmasötik olarak kabul edilebilir tuzlarının kullanımı.
IL148777A (en) Mirtazepine oral oral administration unit
AR027394A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
NO990949L (no) Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av AIDS
WO2004030623A3 (en) Nitroxide radioprotector formulations and methods of use
EP0940141A3 (en) Use of PKC inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
EP0940143A3 (en) Use of PKC-inhibitors for the manufacture of a medicament for the treatment of asthma
MY136408A (en) Active substance combinations and therapies for treating abuse of alcohol
NO990948L (no) Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av HTLV-1-infeksjoner
NO990947L (no) Anvendelse av inhibitorer for PKC til fremstilling av et medikament for behandling av sentralnervesystemsykdommer forbundet med HIV-infeksjon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application